SB 206553, a putative 5-HT<sub>2C</sub> inverse agonist, attenuates methamphetamine-seeking in rats
<p>Abstract</p> <p>Background</p> <p>Methamphetamine (meth) dependence presents a substantial socioeconomic burden. Despite the need, there is no FDA-approved pharmacotherapy for psychostimulant dependence. We consider 5-HT<sub>2C</sub> receptors as viable t...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-06-01
|
Series: | BMC Neuroscience |
Subjects: | |
Online Access: | http://www.biomedcentral.com/1471-2202/13/65 |
id |
doaj-a0c13ca76ecb412499091f4dfff4e2d4 |
---|---|
record_format |
Article |
spelling |
doaj-a0c13ca76ecb412499091f4dfff4e2d42020-11-25T00:25:44ZengBMCBMC Neuroscience1471-22022012-06-011316510.1186/1471-2202-13-65SB 206553, a putative 5-HT<sub>2C</sub> inverse agonist, attenuates methamphetamine-seeking in ratsGraves Steven MNapier T<p>Abstract</p> <p>Background</p> <p>Methamphetamine (meth) dependence presents a substantial socioeconomic burden. Despite the need, there is no FDA-approved pharmacotherapy for psychostimulant dependence. We consider 5-HT<sub>2C</sub> receptors as viable therapeutic targets. We recently revealed that the atypical antidepressant, mirtazapine, attenuates meth-seeking in a rodent model of human substance abuse. Mirtazapine historically has been considered to be an antagonist at 5-HT<sub>2C</sub> receptors, but more recently shown to exhibit inverse agonism at constitutively active 5-HT<sub>2C</sub> receptors. To help distinguish the roles for antagonism <it>vs.</it> inverse agonism, here we explored the ability of a more selective 5-HT<sub>2C</sub> inverse agonist, SB 206553 to attenuate meth-seeking behavior, and compared its effects to those obtained with 5-HT<sub>2C</sub> antagonists, SDZ Ser 082 and SB 242084. To do so, rats were trained to self-administer meth and tested for seeking-like behavior in cue reactivity sessions consisting of contingently presenting meth-associated cues without meth reinforcement. We also explored motor function to determine the influence of SB 206553 and SDZ Ser 082 on motor activity in the presence and absence of meth.</p> <p>Results</p> <p>Like mirtazapine, pretreatment with SB 206553 (1.0, 5.0, and 10.0 mg/kg), attenuated meth-seeking. In contrast, the antagonists, SDZ Ser 082 (0.1, 0.3, and 1.0 mg/kg) and SB 242084 (3.0 mg/kg) had no effect on cue reactivity (CR). SB 242084 (3.0 mg/kg) failed to attenuate the effects of 5.0 and 10 mg/kg SB 206553 on CR. Motor function was largely unaltered by the 5-HT<sub>2C</sub> ligands; however, SB 206553, at the highest dose tested (10.0 mg/kg), attenuated meth-induced rearing behavior.</p> <p>Conclusions</p> <p>The lack of effect by 5-HT<sub>2C</sub> antagonists suggests that meth-seeking and meth-evoked motor activity are independent of endogenous 5-HT acting at 5-HT<sub>2C</sub> receptors. While SB 206553 dramatically impacted meth-evoked behaviors it is unclear whether the observed effects were 5-HT<sub>2C</sub> receptor mediated. Thus, SB 206553 deserves further attention in the study of psychostimulant abuse disorders.</p> http://www.biomedcentral.com/1471-2202/13/65MethamphetamineSerotoninSelf-administrationMotorInverse agonistSeeking |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Graves Steven M Napier T |
spellingShingle |
Graves Steven M Napier T SB 206553, a putative 5-HT<sub>2C</sub> inverse agonist, attenuates methamphetamine-seeking in rats BMC Neuroscience Methamphetamine Serotonin Self-administration Motor Inverse agonist Seeking |
author_facet |
Graves Steven M Napier T |
author_sort |
Graves Steven M |
title |
SB 206553, a putative 5-HT<sub>2C</sub> inverse agonist, attenuates methamphetamine-seeking in rats |
title_short |
SB 206553, a putative 5-HT<sub>2C</sub> inverse agonist, attenuates methamphetamine-seeking in rats |
title_full |
SB 206553, a putative 5-HT<sub>2C</sub> inverse agonist, attenuates methamphetamine-seeking in rats |
title_fullStr |
SB 206553, a putative 5-HT<sub>2C</sub> inverse agonist, attenuates methamphetamine-seeking in rats |
title_full_unstemmed |
SB 206553, a putative 5-HT<sub>2C</sub> inverse agonist, attenuates methamphetamine-seeking in rats |
title_sort |
sb 206553, a putative 5-ht<sub>2c</sub> inverse agonist, attenuates methamphetamine-seeking in rats |
publisher |
BMC |
series |
BMC Neuroscience |
issn |
1471-2202 |
publishDate |
2012-06-01 |
description |
<p>Abstract</p> <p>Background</p> <p>Methamphetamine (meth) dependence presents a substantial socioeconomic burden. Despite the need, there is no FDA-approved pharmacotherapy for psychostimulant dependence. We consider 5-HT<sub>2C</sub> receptors as viable therapeutic targets. We recently revealed that the atypical antidepressant, mirtazapine, attenuates meth-seeking in a rodent model of human substance abuse. Mirtazapine historically has been considered to be an antagonist at 5-HT<sub>2C</sub> receptors, but more recently shown to exhibit inverse agonism at constitutively active 5-HT<sub>2C</sub> receptors. To help distinguish the roles for antagonism <it>vs.</it> inverse agonism, here we explored the ability of a more selective 5-HT<sub>2C</sub> inverse agonist, SB 206553 to attenuate meth-seeking behavior, and compared its effects to those obtained with 5-HT<sub>2C</sub> antagonists, SDZ Ser 082 and SB 242084. To do so, rats were trained to self-administer meth and tested for seeking-like behavior in cue reactivity sessions consisting of contingently presenting meth-associated cues without meth reinforcement. We also explored motor function to determine the influence of SB 206553 and SDZ Ser 082 on motor activity in the presence and absence of meth.</p> <p>Results</p> <p>Like mirtazapine, pretreatment with SB 206553 (1.0, 5.0, and 10.0 mg/kg), attenuated meth-seeking. In contrast, the antagonists, SDZ Ser 082 (0.1, 0.3, and 1.0 mg/kg) and SB 242084 (3.0 mg/kg) had no effect on cue reactivity (CR). SB 242084 (3.0 mg/kg) failed to attenuate the effects of 5.0 and 10 mg/kg SB 206553 on CR. Motor function was largely unaltered by the 5-HT<sub>2C</sub> ligands; however, SB 206553, at the highest dose tested (10.0 mg/kg), attenuated meth-induced rearing behavior.</p> <p>Conclusions</p> <p>The lack of effect by 5-HT<sub>2C</sub> antagonists suggests that meth-seeking and meth-evoked motor activity are independent of endogenous 5-HT acting at 5-HT<sub>2C</sub> receptors. While SB 206553 dramatically impacted meth-evoked behaviors it is unclear whether the observed effects were 5-HT<sub>2C</sub> receptor mediated. Thus, SB 206553 deserves further attention in the study of psychostimulant abuse disorders.</p> |
topic |
Methamphetamine Serotonin Self-administration Motor Inverse agonist Seeking |
url |
http://www.biomedcentral.com/1471-2202/13/65 |
work_keys_str_mv |
AT gravesstevenm sb206553aputative5htsub2csubinverseagonistattenuatesmethamphetamineseekinginrats AT napiert sb206553aputative5htsub2csubinverseagonistattenuatesmethamphetamineseekinginrats |
_version_ |
1725347254050488320 |